Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 6/20 | 0.62 |
| ▸ | CARM1 | Q86X55 | 7/20 | 0.54 |
| ▸ | GRN | P28799 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5067003 | 0.91 | KLKB1 (0.56) | KLKB1CARM1GRNSORT1 | |
| SCHEMBL4562972 | 0.82 | CARM1 (0.64) | CARM1 | |
| SCHEMBL4564149 | 0.82 | CARM1 (0.42) | KLKB1CARM1 | |
| SCHEMBL4586722 | 0.81 | KLKB1 (0.64) | KLKB1CARM1 | |
| SCHEMBL23429118 | 0.80 | KLKB1 (0.62) | KLKB1CARM1GRNSORT1 | |
| SCHEMBL18605228 | 0.78 | KLKB1 (0.59) | KLKB1CARM1GRNSORT1 | |
| SCHEMBL4564122 | 0.78 | KLKB1 (0.43) | KLKB1CARM1GRNSORT1F2 | |
| SCHEMBL4586217 | 0.78 | KLKB1 (1.00) | KLKB1CARM1F2F10PRSS1 | |
| SCHEMBL5471345 | 0.77 | CARM1 (0.63) | KLKB1CARM1 | |
| SCHEMBL5819264 | 0.77 | KLKB1 (0.57) | KLKB1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | KLKB1 4560/4885CARM1 1/4885GRN 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.